Source comparison
Clinical Evidence: Fasted vs Fed-State Tesamorelin Administration
The pivotal Phase 3 trials that led to tesamorelin's FDA approval (published in The Lancet in 2010) used a strict fasted-administration protocol: subjects injected tesamorelin at least four hours after the last meal and waited 30 minutes before eating. This wa
This comparison does not assign a generated winner or score.
- The pivotal Phase 3 trials that led to tesamorelin's FDA approval (published in The Lancet in 2010) used a strict fasted-administration protocol: subjects injected tesamorelin at least four hours after the last meal and waited 30 minutes before eating. This wasn't arbitrary. Preliminary pharmacokinetic studies demonstrated that fed-state administration reduced both Cmax and area under the curve (AUC) by statistically significant margins.
- A 2012 pharmacokinetic substudy published in Clinical Pharmacology & Therapeutics compared tesamorelin absorption under three conditions: fasted (overnight fast, injection upon waking), light meal (300-calorie low-fat meal two hours prior), and high-fat meal (600-calorie meal with 40% fat content two hours prior). Fasted administration produced a mean Cmax of 4.2 ng/mL at 18 minutes post-injection. Light meal administration reduced Cmax to 3.1 ng/mL (26% reduction) with delayed Tmax of 35 minutes. High-fat meal administration produced the most dramatic effect: Cmax of 2.5 ng/mL (40% reduction) with Tmax delayed to 52 minutes.
- The downstream effect on growth hormone pulse was even more pronounced. Fasted-state tesamorelin administration produced a mean GH peak of 12.4 ng/mL at 45 minutes post-injection. Fed-state administration reduced peak GH to 7.8 ng/mL. A 37% reduction that translates directly to reduced IGF-1 elevation over the subsequent 24-hour period. IGF-1 is the primary mediator of tesamorelin's visceral fat reduction effect, so blunted GH pulses mean diminished clinical outcomes.
- What the trials didn't emphasize enough: the difference between fasted and fed administration compounds over weeks. A 30% reduction in absorption per dose becomes a 30% reduction in cumulative IGF-1 exposure over a 12-week protocol. The difference between meaningful visceral adipose tissue reduction and minimal response.